Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
May 14, 2021
- Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
May 13, 2021
- Novo’s Growth Hormone, Teijin’s Osteoporosis Med Skip May Listing
May 13, 2021
- May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
May 12, 2021
- Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
- Kanmin Taiwa Public-Private Confab Set for May 17
May 11, 2021
- MHLW to Fund 7 Development Projects for COVID-19 Therapies
May 11, 2021
- Japan in Talks with 3 Vaccine Makers for Additional Supplies, Eyes 250 Million More Doses
May 10, 2021
- No Impact of Transport Seen on Comirnaty’s mRNA Content or Expression of Spike Proteins: NIHS Study
May 10, 2021
- New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
April 30, 2021
- MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
April 30, 2021
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
- Bayer’s Heart Failure Med Now in Line for June Approval
April 30, 2021
- Large-Scale Vaccination Center to Open in Tokyo on May 24
April 28, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…